Optimization & Automation of Pancreatic Islet Isolation

优化

• 批准号: 6647474
• 负责人: INGRID STUIVER
• 金额: $ 11.96万
• 依托单位: MICROISLET, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-06-01 至 2003-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6647474
• 关键词: baboons; biomedical automation; blood glucose; cell proliferation; cell sorting; cell transplantation; diabetes mellitus; diabetes mellitus therapy; method development; pancreatic islets; swine; tissue /cell preparation

DESCRIPTION (provided by applicant): Islet allotransplatation has been demonstrated to greatly reduce or eliminate the requirement for exogenous insulin injection in patients with insulin-dependent diabetes mellitus. This experimental procedure offers diabetic patients hope for improved blood glucose regulation and, consequently, a reduced risk of long-term complications of the disease. In order to circumvent the problem of human donor tissue availability, the use of animal tissue, particularly that from the pig, has been studied in combination with a technology such as microencapsulation to "immunoisolate" the cells and prevent xenograft rejection. MicroIslets Inc. is developing an improved method for preparation of microencapsulated porcine islet cells for the treatment of Type I diabetes. MicroIslet has used technology licensed from Duke as a basis for generating improved methodology for the isolation, conditioning, storage and microencapsulation of islet cells. Here, we outline new methodology for porcine islet isolation whereby 400,000 islets will be harvested per pancreas. Preliminary data demonstrate that a singe intraperitoneal (ip) injection of encapsulated porcine islet cells prepared using this technology resulted in maintenance of normal blood glucose levels (100-150 mg/dl) in a previously diabetic baboon for 14 months, without the need for additional insulin injections or potentially harmful immunosuppressive drugs to prevent graft rejection.

描述（由申请人提供）：已证明胰岛同种异体移植可大大减少或消除胰岛素依赖性糖尿病患者对外源胰岛素注射的需要。 这一实验过程为糖尿病患者带来了改善血糖调节的希望，从而降低了该疾病长期并发症的风险。 为了解决人类供体组织可用性的问题，已经研究了使用动物组织，特别是来自猪的组织，与微胶囊化等技术相结合，以“免疫隔离”细胞并防止异种移植排斥。 MicroIslets Inc. 正在开发一种改进的方法，用于制备用于治疗 I 型糖尿病的微囊化猪胰岛细胞。 MicroIslet 使用杜克大学许可的技术作为基础，改进了胰岛细胞的分离、调节、储存和微胶囊化方法。 在这里，我们概述了猪胰岛分离的新方法，每个胰腺将收获 400,000 个胰岛。 初步数据表明，单次腹膜内 (ip) 注射使用该技术制备的封装猪胰岛细胞可使先前患有糖尿病的狒狒维持正常血糖水平 (100-150 mg/dl) 14 个月，而无需额外注射注射胰岛素或可能有害的免疫抑制药物以防止移植排斥。